Capital and capability for complex systems
Systems.eco identifies high-stakes systems where conventional approaches have demonstrably failed, and constructs the instruments, platforms and evidence base required for them to function.
We do not look for incremental improvements or adjacent markets. We identify structural failures in high-stakes systems where the absence of the right instrument, the right evidence, or the right market architecture is the proximate cause of preventable harm.
We distinguish between markets that are difficult and markets that are broken by design. Our work begins where conventional instruments end: at the boundary of what finance has chosen not to solve.
We do not consult. We build. Each venture constructs the missing infrastructure: the pricing methodology, the verification standard, the clinical dataset, the exchange architecture that allows a market to exist.
Rigour is not a constraint on ambition; it is the condition for it. We invest in generating the evidence base that allows institutional capital to follow with confidence.
The competitive moat in each venture is the accumulated dataset: priced transactions, verified outcomes, demonstrated correlations. Early deployment creates compounding informational advantage that deepens with each iteration.
Resilient Aid Parametric Insurance Deployment (RApid) is a structured finance platform addressing the fundamental design flaw in humanitarian response: capital is deployed reactively, after loss has occurred, when it is most expensive and least effective. RApid structures pre-disaster parametric instruments that trigger on physical signals, moving humanitarian finance from reactive to anticipatory. The first programme targets a three-country Sahel corridor, providing sovereign-level coverage and enabling development finance institutions and multilateral development banks to deploy blended capital with measurable social return. The platform's durable advantage is the accumulating transaction dataset that enables progressively more precise risk pricing and portfolio construction.
CRCX is a research and market infrastructure company. Its purpose is to investigate whether a dedicated exchange for carbon dioxide removal credits addresses a genuine and material need in the market for climate finance and, if the evidence supports that conclusion, to design and establish that exchange. Carbon removal credits are physically and legally distinct from the avoidance offsets that constitute the majority of voluntary carbon market activity in that they evidence the extraction and durable storage of CO₂ already present in the atmosphere, rather than emissions that did not occur. No exchange dedicated exclusively to this category currently exists, and the absence of one is a meaningful constraint on project finance for removal technologies, corporate procurement at scale, and institutional investment in the sector. The company is currently conducting a structured market study, developing a contract specification for a tradeable removal credit unit, and preparing a UK grant application to fund the research and proof-of-concept phase.
PiFX addresses the original sin of development finance: sovereign and sub-sovereign borrowers in emerging markets and developing economies are typically required to borrow in hard currencies, creating FX exposure that can render viable projects unviable when local currencies depreciate. PiFX structures instruments that insulate local borrowers from currency devaluation risk, enabling development lending to function as intended. The platform targets DFI lending programmes, multilateral facilities, and bilateral development instruments where currency mismatch is a systemic constraint on deployment. By resolving the FX problem at instrument level rather than project level, PiFX creates a scalable solution applicable across the full pipeline of development lending.
SeaCrunch is building the clinical and commercial foundation for marine protein as a mainstream nutritional category. Despite a global seaweed market projected to exceed £13bn by 2034 and growing institutional interest in alternative proteins, no human randomised controlled trial has established muscle protein synthesis rates for marine protein sources. This absence of gold-standard clinical evidence is the proximate constraint on institutional adoption, regulatory confidence, and commercial scale. SeaCrunch, in partnership with the University of Exeter and the Scottish Association for Marine Science, is preparing a Phase 1 clinical programme to generate the evidence base the sector requires. The platform then provides the commercial and licensing infrastructure to translate that evidence into market access.
"We do not solve problems at their surface. We look for the layer that is missing, and we build it."
Every venture begins with a structured diagnosis. We distinguish between problems that are hard and problems that are broken by design, between markets that lack capital and markets that lack the instrument that would allow capital to flow.
The methodology draws on advanced quantitative approaches to risk pricing, scenario construction, and portfolio allocation, adapted for markets where data is sparse and correlations are non-obvious. Where appropriate, we integrate forward-looking scenario discipline with Bayesian recalibration to improve precision as transactions accumulate.
We work with institutional partners, not around them. Development finance institutions, multilateral development banks, verification bodies, and university research partners are structural components of each venture, not afterthoughts.
The social return is the primary metric in concessional capital conversations. We deploy modest multipliers not as a sales argument but as evidence that the instrument is correctly calibrated.
Our work is designed to withstand the scrutiny of institutions that take their mandate seriously.
DFIs and MDBs seeking deployable instruments at the frontier of blended finance. Our ventures are designed for institutions with a mandate to move capital into difficult markets, with the rigour their credit committees require and the social return their mandates demand. BII, FCDO, KfW, IFC, and comparable institutions.
Asset managers, sovereign wealth funds, and ESG-mandated investors seeking exposure to high-integrity climate assets, emerging market instruments, or early-stage ventures with demonstrable structural advantage. We provide the evidence base and the methodology to support serious due diligence.
National governments, multilateral agencies, and policy bodies seeking evidence-based instruments for climate resilience, food security, or development finance reform. We engage at the intersection of policy intent and financial execution, where the gap between mandate and deployment is most consequential.
Systems.eco was founded on the conviction that the most consequential problems are rarely unsolvable. More often, they have not been approached with the right combination of intellectual rigour, financial innovation, and patience for the foundational work that institutional confidence requires.
Our team brings three decades of capital markets experience, quantitative methodology, and cross-sector partnership development. We operate across jurisdictions, partner with leading academic institutions, and work within established regulatory frameworks rather than around them.
Each venture is deployed only when the foundational layer is sufficiently developed to withstand institutional scrutiny. We invest in getting the methodology right before we invest in scale.
Our ventures are designed to integrate with the regulatory, verification, and governance frameworks that DFIs, MDBs, and policy bodies operate within. We build on established standards rather than competing with them.
Transaction datasets, clinical evidence, and priced risk histories are the compounding intellectual property in each venture. We deploy early to accumulate data that enables progressively more precise and defensible instruments.
In correctly designed instruments, the two are not in tension. We regard modest social return multipliers as evidence that an instrument is appropriately calibrated, not as a concession to impact investors.
Our ventures are at different stages of development. We present each one honestly. Where clinical evidence is still being generated or where pricing methodology is subject to further calibration, we say so.
We welcome enquiries from development finance institutions, multilateral development banks, institutional investors, and research partners with a genuine interest in the ventures described.
We do not pitch to audiences who have not asked to hear us. If you have arrived here through your own research, we are glad you did. Please tell us why.
Systems.eco is the parent platform for a portfolio of early-stage ventures in structured finance, climate markets, and food systems science. Regulatory status varies by venture jurisdiction.